Charpidou A - Search Results

1

Malignant Superior Vena Cava Syndrome: State of the Art.

Patriarcheas V, Grammoustianou M, Ptohis N, Thanou I, Kostis M, Gkiozos I, Charpidou A, Trontzas I, Syrigos N, Kotteas E, Dimakakos E. Patriarcheas V, et al. Among authors: charpidou a. Cureus. 2022 Jan 4;14(1):e20924. doi: 10.7759/cureus.20924. eCollection 2022 Jan. Cureus. 2022. PMID: 35004083 Free PMC article. Review.

2

Developments in the treatment of non-small cell lung cancer.

Gkiozos I, Charpidou A, Syrigos K. Gkiozos I, et al. Among authors: charpidou a. Anticancer Res. 2007 Jul-Aug;27(4C):2823-7. Anticancer Res. 2007. PMID: 17695454 Free article. Review.

3

Therapy-induced toxicity of the lungs: an overview.

Charpidou AG, Gkiozos I, Tsimpoukis S, Apostolaki D, Dilana KD, Karapanagiotou EM, Syrigos KN. Charpidou AG, et al. Anticancer Res. 2009 Feb;29(2):631-9. Anticancer Res. 2009. PMID: 19331213 Free article. Review.

4

Targeted therapy for nonsmall cell lung cancer: focusing on angiogenesis, the epidermal growth factor receptor and multikinase inhibitors.

Kotteas EA, Charpidou AG, Syrigos KN. Kotteas EA, et al. Among authors: charpidou ag. Anticancer Drugs. 2010 Feb;21(2):151-68. doi: 10.1097/CAD.0b013e328334da02. Anticancer Drugs. 2010. PMID: 20016368 Review.

5

Triplet combination of carboplatin, irinotecan, and etoposide in the first-line treatment of extensive small-cell lung cancer: a single-institution phase II study.

Charpidou A, Tsagouli S, Tsimpoukis S, Vassias A, Makrilia N, Stratakos G, Gkiozos I, Syrigos K. Charpidou A, et al. Anticancer Drugs. 2010 Jul;21(6):651-5. doi: 10.1097/CAD.0b013e3283393718. Anticancer Drugs. 2010. PMID: 20386306 Clinical Trial.

6

Bronchial washing levels of vascular endothelial growth factor receptor-2 (VEGFR2) correlate with overall survival in NSCLC patients.

Charpidou A, Gkiozos I, Konstantinou M, Eleftheraki A, Demertzis P, Harrington K, Polyzos A, Syrigos KN. Charpidou A, et al. Cancer Lett. 2011 May 28;304(2):144-53. doi: 10.1016/j.canlet.2011.02.018. Cancer Lett. 2011. PMID: 21396771 Clinical Trial.

7

Levels of vascular endothelial growth factor in serum and pleural fluid are independent predictors of survival in advanced non-small cell lung cancer: results of a prospective study.

Gkiozos I, Tsagouli S, Charpidou A, Grapsa D, Kainis E, Gratziou C, Syrigos K. Gkiozos I, et al. Among authors: charpidou a. Anticancer Res. 2015 Feb;35(2):1129-37. Anticancer Res. 2015. PMID: 25667503

8

Bone metastases in patients with small cell lung carcinoma: rate of development, early versus late onset, modality of treatment, and their impact on survival. A single-institution retrospective cohort study.

Charpidou A, Tsagouli S, Gkiozos I, Grapsa D, Moutsos M, Kiagia M, Syrigos K. Charpidou A, et al. Clin Exp Metastasis. 2016 Jun;33(5):453-60. doi: 10.1007/s10585-016-9789-7. Epub 2016 May 21. Clin Exp Metastasis. 2016. PMID: 27209468

9

PET/CT and brain MRI role in staging NSCLC: prospective assessment of the accuracy, reliability and cost-effectiveness.

Gkogkozotou VI, Gkiozos IC, Charpidou AG, Kotteas EA, Boura PG, Tsagouli SN, Syrigos KN. Gkogkozotou VI, et al. Among authors: charpidou ag. Lung Cancer Manag. 2018 May 31;7(2):LMT02. doi: 10.2217/lmt-2018-0008. eCollection 2018 Jun. Lung Cancer Manag. 2018. PMID: 30643581 Free PMC article.

10

Towards precision medicine: CCL2, another brick in the wall?

Charpidou A, Kotteas E, Gaga M. Charpidou A, et al. Eur Respir J. 2019 Mar 7;53(3):1802327. doi: 10.1183/13993003.02327-2018. Print 2019 Mar. Eur Respir J. 2019. PMID: 30846448 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

73 results

Search Page